利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.026 秒)

    Dosing methods for treating disease
    2.
    发明授权
    Dosing methods for treating disease 有权
    给药方法治疗疾病

    公开(公告)号：US09161946B2

    公开(公告)日：2015-10-20

    申请号：US14101449

    申请日：2013-12-10

    申请人： Anadys Pharmaceuticals, Inc.

    发明人： James Appleman ,  Joyce Tan ,  Simon Fletcher

    IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7064 ,  A61K31/40

    CPC分类号： A61K31/7064 ,  A61K31/40 ,  Y02A50/463

    摘要： The invention relates to a method for treating disease such as viral infections, tumors, and cancers, comprising administering a TLR7 agonist or TLR7 agonist prodrug according to a cyclical dosing schedule having a dosing period and a resting period. For example, the method encompasses treating disease with: 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one Tosylate according to a dosing schedule of every-other-day or a dosing schedule of three consecutive days of dosing followed by four consecutive days of not dosing.

    摘要翻译： 本发明涉及用于治疗疾病如病毒感染，肿瘤和癌症的方法，包括根据具有给药期和静息期的循环给药方案施用TLR7激动剂或TLR7激动剂前药。 例如，该方法包括用以下化合物治疗疾病：5-氨基-3-（2'-O-乙酰基-3'-脱氧-β-呋喃核糖基）-3H-噻唑并[4,5-d]嘧啶-2 根据每一天的给药方案或连续三天给药的给药方案，然后连续四天不给药，一次甲苯磺酸酯。

    Passive personal vocal monitor
    4.
    发明授权
    Passive personal vocal monitor 有权
    被动个人声乐显示器

    公开(公告)号：US08061473B1

    公开(公告)日：2011-11-22

    申请号：US12853404

    申请日：2010-08-10

    申请人： Steven D. Kerr

    发明人： Steven D. Kerr

    IPC分类号： A61B7/02 ,  A61F2/20 ,  H03G3/00 ,  H04R5/02 ,  H04R29/00

    CPC分类号： H04R1/1016 ,  A61F11/008 ,  H04R1/345

    摘要： A passive personal vocal monitor is described for enhancing the sound of a singer's voice to the singer during a performance. The monitor has an earpiece with a nipple configured to be disposed snuggly within the singer's ear and having an internal channel terminating in an open end adjacent the singer's eardrum. A tubular acoustic waveguide extends from the earpiece to an open end that is positionable adjacent the singer's mouth when the nipple is in the singer's ear. A canal in the earpiece couples the tubular waveguide to the channel of the nipple so that sounds of the singer's voice are conveyed along the waveguide and to the user's eardrum during a singing performance. An adjustable ambient sound inlet is provided on the earpiece so that a singer may admit a desired amount of ambient sound to be mixed with his voice as he sings.

    摘要翻译： 被动的个人声乐监视器被描述为在表演期间增强歌手对声音的声音。 显示器具有耳机，其具有接头，其配置为在歌手的耳朵内紧密地设置，并且具有终止于与歌手的鼓膜相邻的开放端的内部通道。 管状声波导从耳机延伸到开口端，当乳头处于歌手的耳朵中时，该开口端可邻近歌手的嘴定位。 听筒中的运河将管状波导连接到乳头的通道，使得歌手的声音在歌唱演奏期间沿着波导传送到用户的鼓膜。 耳机上设有一个可调节的环境声音入口，使得歌手可以在他唱的时候接受与他的声音混合的所需量的环境声音。

    GLP-1 receptor agonists for islet cell transplantation
    5.
    发明授权
    GLP-1 receptor agonists for islet cell transplantation 有权
    GLP-1受体激动剂用于胰岛细胞移植

    公开(公告)号：US09161953B2

    公开(公告)日：2015-10-20

    申请号：US13996093

    申请日：2011-12-20

    申请人： Kwame Osei

    发明人： Kwame Osei

    IPC分类号： A01N63/00 ,  A61K38/43 ,  A61K35/39 ,  A61K38/26 ,  A61K38/16

    CPC分类号： A61K35/39 ,  A61K38/16 ,  A61K38/26

    摘要： The disclosure provides methods for treating diabetes by promoting graft survival and improved graft function in a patient receiving an islet transplant by treating the patient with a GLP-1 receptor agonist compound prior to the islet transplant. The methods may also comprise treating the islets with a GLP-1 receptor agonist compound prior to transplanting them in a patient. The methods may eliminate the need for immunosuppressive therapy in islet transplants. Any GLP-1 receptor agonist compound know in the art can be used in the methods described herein.

    摘要翻译： 本公开提供了通过在胰岛移植之前通过用GLP-1受体激动剂化合物治疗患者来促进接受胰岛移植的患者中的移植物存活和改善移植物功能来治疗糖尿病的方法。 所述方法还可以包括在将它们移植到患者体内之前用GLP-1受体激动剂化合物处理胰岛。 该方法可以消除胰岛移植中免疫抑制治疗的需要。 本领域已知的任何GLP-1受体激动剂化合物可用于本文所述的方法。

    Methods and compositions for inhibiting the growth of hematopoietic malignant cells
    7.
    发明授权
    Methods and compositions for inhibiting the growth of hematopoietic malignant cells 有权
    抑制造血恶性细胞生长的方法和组合物

    公开(公告)号：US08911950B2

    公开(公告)日：2014-12-16

    申请号：US13220307

    申请日：2011-08-29

    申请人： Ginette Serrero

    发明人： Ginette Serrero

    IPC分类号： C07K16/22 ,  A61K45/06 ,  G01N33/574 ,  A61K39/395 ,  A61K31/573 ,  C07K14/475 ,  A61K39/00 ,  A61K38/00

    CPC分类号： A61K31/573 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/475 ,  C07K16/22 ,  C07K2317/73 ,  C12N2799/026 ,  G01N33/57426 ,  G01N2800/52 ,  A61K2300/00

    摘要： Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.

    摘要翻译： 本文公开了用于减少造血恶性细胞（例如B细胞白血病细胞）的生长的组合物和方法。 该方法涉及通过将造血恶性细胞与GP88拮抗剂接触来减少造血恶性细胞的生长。 GP88是促进造血恶性细胞生长的88 KDa自分泌生长因子。 提供GP88的拮抗剂抑制其表达或生物活性。 拮抗剂包括反义寡核苷酸和抗体。 还提供了用于确定患者是否响应或对抗癌疗法（例如，糖皮质激素治疗）有反应的方法。 造血细胞中GP88水平的升高表明患者没有反应或对抗癌治疗有反应。

    Method of preparing deoxyribofuranose compounds
    8.
    发明授权
    Method of preparing deoxyribofuranose compounds 有权
    脱氧呋喃核糖化合物的制备方法

    公开(公告)号：US08829168B2

    公开(公告)日：2014-09-09

    申请号：US13129730

    申请日：2009-11-16

    申请人： Gregory J. Haley

    发明人： Gregory J. Haley

    IPC分类号： C07H1/00 ,  C07H9/04

    CPC分类号： C07H9/04 ,  C07D307/20

    摘要： The invention relates to methods for making deoxyribofuranose compounds such as compound (2) which are useful intermediates in the preparation of pharmaceutical compounds such as 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.

    摘要翻译： 本发明涉及制备脱氧呋喃核糖化合物的方法，例如化合物（2），其是制备药物化合物如5-氨基-3-（2'-O-乙酰基-3'-脱氧-β- - 呋喃核糖基）-3H-噻唑并[4,5-d]嘧啶-2-酮等。

    Sugar transporters
    9.
    发明授权
    Sugar transporters 有权
    糖运输商

    公开(公告)号：US09562081B2

    公开(公告)日：2017-02-07

    申请号：US12773500

    申请日：2010-05-04

    申请人： Wolf B. Frommer ,  Sylvie Lalonde

    发明人： Wolf B. Frommer ,  Sylvie Lalonde

    IPC分类号： C12N15/113 ,  C12N15/82 ,  C07K14/47 ,  C07K14/415 ,  C07K14/435

    CPC分类号： C12N15/8279 ,  C07K14/415 ,  C07K14/43545 ,  C07K14/47 ,  C12N15/8218 ,  C12N15/8245 ,  C12N15/8246

    摘要： A novel class of transporter protein, referred to as SWEET, GLUE or Glü, is disclosed. These transporters provide a novel system for the transportation of sugars across membranes within a cell and between the inside and outside of a cell. Such transporters are useful for understanding and altering the sugar concentration within certain organs of an organism, and within certain organelles within the cell. These transporters are also useful in protecting plants from a pathogen attack.

    摘要翻译： 公开了一类新颖的转运蛋白，称为SWEET，GLUE或Glü。 这些转运蛋白提供了一种用于在细胞内和细胞内部和外部的膜之间运输糖的新型系统。 这样的转运蛋白可用于理解和改变生物体的某些器官内和细胞内的某些细胞器内的糖浓度。 这些转运蛋白也可用于保护植物免受病原体攻击。